Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBIT Margin (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed EBIT Margin for 7 consecutive years, with 90.52% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 375217.0% to 90.52% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 104.25% through Dec 2025, up 16297.0% year-over-year, with the annual reading at 104.25% for FY2025, 16297.0% up from the prior year.
  • EBIT Margin hit 90.52% in Q4 2025 for BridgeBio Pharma, up from 120.3% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.16% in Q1 2024 to a low of 38200.0% in Q3 2022.
  • Historically, EBIT Margin has averaged 7504.11% across 5 years, with a median of 5116.28% in 2023.
  • Biggest YoY gain for EBIT Margin was 10284304bps in 2021; the steepest drop was -3881206bps in 2021.
  • Year by year, EBIT Margin stood at 1656.14% in 2021, then tumbled by -317bps to 6910.8% in 2022, then plummeted by -47bps to 10167.11% in 2023, then skyrocketed by 62bps to 3842.69% in 2024, then surged by 98bps to 90.52% in 2025.
  • Business Quant data shows EBIT Margin for BBIO at 90.52% in Q4 2025, 120.3% in Q3 2025, and 121.45% in Q2 2025.